p53 HETEROBIFUNCTIONAL CONJUGATES AND USES THEREOF
Heterobifunctional molecules targeting p53 Y220C mutant proteins restore normal p53 activity, inducing cell cycle arrest and apoptosis in cancer cells, addressing the limitations of existing cancer treatments.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- DESIGN THERAPEUTICS INC
- Filing Date
- 2025-11-14
- Publication Date
- 2026-05-21
AI Technical Summary
Current treatments for cancer, particularly those targeting mutated p53 proteins, are ineffective in restoring normal p53 activity and do not adequately address the transcriptional dysregulation caused by these mutations.
Development of heterobifunctional molecules that noncovalently bind to p53 Y220C mutant proteins, incorporating a p53-binding moiety and a protein-binding moiety linked by a specific structure, capable of reversing or promoting the transcriptional activity of p53 Y220C through interaction with endogenous regulatory proteins.
These molecules effectively reinstate normal p53 activity, leading to cell cycle arrest and apoptosis in cancer cells with mutated p53, while sparing wild-type p53 cells, thus providing a targeted therapeutic approach.
Smart Images

Figure US2025055663_21052026_PF_FP_ABST